JCO Clinical Cancer Informatics

Background: Circulating tumour DNA (ctDNA) liquid biopsy is now established across oncology for early cancer detection, minimal residual disease surveillance, and treatment monitoring. Detection thresholds for all current ctDNA assays are derived empirically through receiver operating characteristic analysis on training cohorts - a statistically valid but theoretically uninformed approach that does not specify the minimum detectable tumour fraction given assay technical characteristics, nor identify when increasing sequencing depth ceases to provide additional clinical information. Methods: We model ctDNA detection as a binary hypothesis testing problem with Binomial-distributed mutant allele counts against a sequencing error noise floor. The Neyman-Pearson lemma is applied to derive the uniformly most powerful detector and the minimum detectable tumour fraction in closed form. The sequencing assay is modelled as a binary symmetric channel and Shannon channel capacity is calculated. Empirical validation uses n=61 data points extracted from five published peer-reviewed analytical validation studies across five independent institutions in the US and EU (2018 - 2025): Yu et al. 2022, Stetson et al. 2018, Frydendahl et al. 2023, Northcott et al. 2024, and Cheng et al. 2025. Results: The minimum detectable tumour fraction is derived in closed form as f_min approximately equal to (z_alpha + z_beta) multiplied by the square root of (epsilon divided by N), where N is sequencing depth, epsilon is the platform error rate, and z_alpha, z_beta are standard normal quantiles at the specified false positive and false negative rates. Shannon channel capacity is C = 1 minus H(epsilon) bits per read, where H(epsilon) is binary entropy. Empirical validation yields 84.3% agreement for single-locus assays. Discordance for multi-locus tumour-informed assays (NeXT Personal, duplex WGS) is consistent with the single-locus model scope and identifies the principal theoretical extension required. Conclusions: This framework provides the first formal Neyman-Pearson optimality proof for ctDNA detection, a closed-form detection limit, and a platform-independent efficiency metric for NHS and regulatory standardisation. Keywords: circulating tumour DNA; liquid biopsy; Neyman-Pearson detection; Shannon channel capacity; sequencing depth; limit of detection; minimal residual disease; signal detection theory

Post-surgical adverse outcomes, including mortality, intensive care readmission, and complications, remain major challenges for clinical decision-making. Existing machine learning approaches focus on outcome prediction while operating as opaque systems, limiting clinical trust and the translation of predictions into treatment decisions, and many clinical studies rely on synthetic data in which shared intermediate variables create circular dependencies between inputs and targets that compromise reported performance. We aimed to develop an explainable multimodal architecture and a rigorous evaluation methodology that address these gaps. We designed a two-stage architecture integrating supervised deep learning for risk prediction with conservative Q-learning for action recommendation. The first stage uses five modality-specific encoders for structured records, physiological time-series, chest radiographs, clinical notes, and surgical metadata, unified through cross-modal attention into a shared patient-state representation. The second stage applies offline reinforcement learning to recommend clinical actions while preventing value overestimation. We formally characterized a target-leakage flaw in synthetic pipelines and propose a real-data methodology using a verified clinical database, with event-censored temporal separation and uncertainty-weighted per-task training. Component-level behavior was validated on a controlled synthetic benchmark, demonstrating that the architecture functions as designed without claiming clinical validity. The cross-modal attention and risk-prediction components behaved as expected, whereas the offline reinforcement learning stage did not converge on the benchmark, indicating that value estimation requires further investigation on real clinical data. The architecture provides dual-level explainability through attention visualization and value decomposition, contributing a deployable design, a formal methodological critique of synthetic-data practices, and a complete framework for clinically valid evaluation.

Cancer treatment has shifted toward personalized therapy based on molecular profiling, particularly in advanced disease. Existing circulating tumor DNA panels are often broad, generating many non-actionable variants and incurring costs that limit routine use in molecular tumor boards. We developed and validated a manufacturer-independent, 109-gene liquid biopsy-centered pan-cancer open next generation sequencing panel (LION panel), combined with an in-house bioinformatic pipeline to support clinical decision-making. A total of 87 samples were analyzed, including 17 reference samples, 21 healthy blood donor controls, and 49 patient samples including nine tumor entities. The LION panel achieved 92% sensitivity and 99% specificity in reference samples, with high concordance to digital droplet PCR (r = 0.99). It detected variant allele frequencies as low as 0.05% (tumor-informed) and 0.5% (tumor-uninformed). Clinical concordance reached 82% with blood-based digital droplet PCR and 75% with whole exome tissue sequencing. In representative cases, variant dynamics correlated with disease progression and revealed additional targetable variants. Overall, the LION panel supports clinical decision-making by enabling identification of targetable variants, disease monitoring, and detection of treatment resistance, particularly when tumor tissue is unavailable.

Objective: Clinical phenotyping methods that rely on clinical and informatics expertise can be time-intensive and costly. We tested both manual and highly automated approaches using electronic health record (EHR) data to identify an FDA Sentinel Initiative health outcome of interest, acute pancreatitis. Materials and Methods: We trained and evaluated machine learning algorithms using EHR data with two approaches: a custom approach that included manually curated features and trained on outcomes data validated with medical record review, and a highly automated approach that greatly simplifies and automates feature engineering and relies on low-cost silver-standard outcomes for model training. Results: Custom algorithms using manually curated structured claims data discriminated cases from non-cases with a high degree of accuracy (cv-AUC 0.89 [95%CI 0.84-0.94]); the inclusion of natural language processing (NLP)-derived covariates from clinical notes increased performance slightly (cv-AUC 0.91[95%CI 0.86-0.97]). The automated algorithm trained on the outcome count of diagnosis codes performed less well (AUC 0.80 [95% CI 0.75-0.85]) but improved using maximum lipase value as an outcome (AUC 0.88 [95% CI 0.84-0.92]). At a positive predictive value of 90%, the custom algorithm had a sensitivity of 92%, the automated algorithm trained on diagnosis code count had a sensitivity of 45%, and the automated algorithm trained on maximum lipase value had a sensitivity of 84%. However, a prediction rule derived by clinicians during chart review was nearly as accurate (maximum lipase value [≥] 3 times upper limit of normal; AUC 0.86, PPV 85%, sensitivity 92%). Discussion: Machine learning algorithms with manually curated structured data and NLP features trained on validated outcomes data successfully identified validated events. Use of an outcome in the automated model based on specific phenotype knowledge (maximum lipase value) allowed for performance similar to the custom model and with considerably less resources.

Objective. To introduce PsiBench, a clinically validated medication-safety benchmark for evaluating large language models (LLMs) against the standards used to certify hospital computerized provider order entry (CPOE) and electronic health record (EHR) systems, and a non-overlapping three-tier evaluation framework separating highest-stakes discrimination, the operational CDS regime, and category-correct alerting. Materials and Methods. PsiBench comprises 492 medication-safety scenarios across 11 safety categories, created by clinical pharmacology experts whose work underpins an annualized testing procedure used by more than 2,000 U.S. hospitals. The three-tier framework partitions the scenarios non-overlappingly: Discrimination (98 scenarios, 50 fatal vs 48 deception, near-balanced 51%/49%); Operational (394 scenarios, 261 serious unsafe plus 133 safe including 41 Excessive Alerts reclassified as operational negatives); and Attribution (311 alert-required scenarios). We evaluated 40 frontier LLMs from 10 providers over 3 runs per scenario at temperature 0.2 (or the provider default where temperature is not configurable), yielding 59,040 evaluations conducted April 21-23, 2026. Results. Headline binary performance on the full benchmark spans a wide range across the 40 models: F1 78.5%-92.3%, accuracy 65.4%-89.8%, sensitivity 81.4%-100.0%, specificity 6.1%-81.8%. Leading models by F1 (o4-mini 92.3%; o3 92.2%) pair high sensitivity with meaningful specificity; three models saturate sensitivity at 100% but fall below 25% specificity, indistinguishable from a naive always-alert classifier. The wide spread on a single headline metric motivates tier-specific analyses, developed in a separate clinical paper. Discussion and Conclusion. PsiBench and the three-tier framework operationalize a rigorous evaluation rubric for LLM medication safety, grounded in two decades of national hospital audit experience. The framework generalizes to any binary medication-safety classifier (rule-based, conventional ML, or LLM-driven), supporting tier-aware model selection and post-deployment surveillance.

In primary care and outpatient settings, clinically important patient information is often embedded in fragmented, ambiguous, repetitive, and noisy communication between physicians and patients. This limits physicians ability to obtain a clear preconsultation overview of symptoms, history of present illness, and visit intent, while also preventing real world clinical dialogues from being reused in hospital information systems and medical artificial intelligence applications. To address this challenge, we developed PCRAgent, a centrally coordinated multi agent framework for preconsultation clinical information organization. Guided by physician inquiry logic, PCRAgent identifies, extracts, corrects, and standardizes patient-reported information from noisy consultations. Its coordinated modules including error detection, semantic editing, output control, contextual memory, and intent recognition enable robust parallel handling of spelling errors, repetitions, grammatical inconsistencies, medical ambiguities, and non-medical interference. A traceable edit list records intermediate corrections and context, allowing iterative refinement without redundant modifications. PCRAgent generates two complementary outputs. One is a PreConsultation Clinical Report for rapid physician review. The other is a Structured Clinical Conversation Dataset for hospital data construction and downstream AI applications. In evaluations using 220000 strongly perturbed consultations, PCRAgent maintained high robustness, achieving a clinical information accuracy of 4.99 out of 5 and key element completeness of 5 out of 5, outperforming GPT4o. Expert review of Chinese and English dialogues confirmed high clinical accuracy of 4.85 out of 5 and high safety of 4.79 out of 5. Multicenter validation in real-world outpatient workflows further demonstrated practical utility. These findings indicate that PCRAgent can efficiently transform noisy and unstructured consultations into physician ready reports and AI ready structured data, improving outpatient efficiency, reducing cognitive burden, ensuring information completeness, supporting precise decision-making, and enabling high-quality reuse of clinical data.

Background Machine learning (ML) models are increasingly used to predict adverse outcomes after surgery. However, most rely on static patient characteristics (e.g., age, comorbidities) and overlook clinician-controlled treatment decisions that can be actively modified at the point of care. Discharge opioid prescribing is a key modifiable, clinician-controlled decision, yet optimizing prescribing choices across multiple adverse outcomes remains underexplored in predictive modeling. This study addresses that gap by introducing a novel ML framework that explicitly separates fixed patient risk factors from modifiable prescribing options to support personalized, risk-informed opioid prescribing decisions. Methods We developed the Hierarchical Clinical Fusion Transformer (HCF-Transformer), an ML model designed to estimate patient-specific risks across four postoperative outcomes: prolonged opioid use (POU), chronic pain (CP), 30-day readmission, and opioid-associated outcomes (OAO). The model constructs patient risk profiles from fixed, non-modifiable baseline factors, followed by a transformer layer. Clinician-controllable discharge opioid regimens are modeled as alternative intervention candidates and fused with the fixed risk representation through a clinical fusion mechanism, enabling assessment and ranking based on predicted risks. A Total Relative Risk (TRR) metric, calibrated to each outcome prediction threshold, guides the recommendation process. We evaluated the model in diabetic surgical patients, a common high-risk population. Results The study included 157,853 unique diabetic surgical patients, with outcome prevalences ranging from 47.2% (POU) to 1.8% (OAO). The HCF-Transformer achieved the highest AUROCs, 0.798 for POU, 0.712 for 30-day readmission, 0.808 for CP, and 0.922 for OAO, outperforming Random Forest, FT-Transformer, and ResNet-based models. Compared to these baselines, HCF-Transformer generated more stable and discriminative risk estimates and demonstrated significant variation in TRR scores across discharge opioid options (ANOVA p < .01, eta-squared > .01). This enabled consistent identification of lower-risk regimens tailored to patient-specific profiles. Conclusions The HCF-Transformer introduces a novel hierarchical fusion approach to optimize opioid prescribing by integrating static patient risk profiles with modifiable discharge options. Using transformer-based modeling and a quantifiable TRR metric, the model delivers personalized, risk-aware recommendations. This approach enables data-driven opioid prescribing tailored to individual risk and has the potential to improve postoperative outcomes in high-risk populations. Our findings demonstrate that integrating modifiable factors with structured risk profiles through a transformer-based fusion architecture can enhance decision-support systems, paving the way for more actionable and personalized AI in healthcare.

Objective: To evaluate whether a locally hosted open-weight large language model (LLM) can extract documented psychosocial factors from pediatric psychiatric intake notes and apply validated extraction to a large emergency psychiatry cohort. Materials and Methods: We identified emergency department presentations at Cincinnati Children's Hospital Medical Center from January 1, 2016, through December 31, 2024, among patients younger than 18 years with psychiatric billing diagnoses. Using full-text intake notes, gpt-oss:120b classified peer conflict, sleep disruption, and school-related academic, attendance, and disciplinary issues as detected, negated, or indeterminate. Four human raters independently reviewed 50 notes. We compared Fleiss' kappa among humans alone versus humans plus the LLM, assessed repeated-query stability across 50 independent calls per note, and applied the workflow to all eligible notes. Results: Among 37,315 eligible admissions, 22,284 had eligible intake notes; 22,270 produced parseable JSON. In detected-versus-not-detected coding, human-plus-LLM reliability did not differ significantly from human-only reliability across measures (human {kappa} 0.71-0.94; human-plus-LLM {kappa} 0.70-0.93). Stability was associated with human agreement: mean LLM-human agreement increased from 42.6% for classifications with less than 80% stability to 82.7% for classifications with 100% stability (Pearson r = 0.36). Full-cohort extraction showed frequent and overlapping documented factors: sleep disruption was most frequently detected (57.7%), followed by peer conflict (47.2%), academic issues (43.4%), disciplinary issues (43.3%), and attendance issues (16.9%). Discussion: Agreement varied by construct and was strongest when repeated model outputs were stable. Conclusion: Locally hosted open-weight LLMs can support scalable structured extraction of documented psychosocial factors from pediatric psychiatric intake notes after local validation.

End-of-rotation handoffs are critical for patient safety but add to documentation burden for hospitalists. Generative artificial intelligence (AI) may help automate handoff creation using electronic health record data, but its impact on quality and safety is unclear. Methods: We developed an AI handoff tool with a large language model using clinical notes as input and conducted a retrospective evaluation comparing AI-generated and clinician-authored handoffs. Handoffs were assessed across domains of quality and safety through a structured review. Results: Quality ratings were similar between AI and human handoffs (3.7 vs. 3.5, p=0.57). AI-generated handoffs were rated higher for organization (4.4 vs. 4.1, p=0.05) and completeness (4.1 vs. 3.6, p=0.01), but lower for conciseness (3.7 vs. 4.1, p=0.03) and accuracy (4.1 vs. 4.4, p=0.03). Error rates were comparable (0.3/handoff in both groups); however, AI-generated handoffs included inaccuracies (9% of AI errors) and hallucinations (1% of AI errors), while clinician-authored handoffs contained only omissions. Conclusion: Human and AI handoffs have differing error profiles and tradeoffs between completeness and conciseness. Prospective evaluation in clinical workflows is underway.

Background: Machine learning models for stroke mortality prediction typically treat each time horizon independently and use flat tabular features that ignore the relational structure of electronic health records (EHRs). In this pilot study, we leveraged graph-based machine learning models to predict post stroke all-cause-mortality across three different time horizons. Methods: We developed Stroke Temporal Heterogeneous Graph (StrokeTHG), a heterogeneous graph neural network model for simultaneous multi-horizon stroke mortality prediction (30-day, 90-day, 1-year) using EHR data from Penn State Health System. The model encodes various relations among EHR entities (e.g., patient, diagnosis, comorbidity) and temporal encoding of admission time to better predict stroke mortality. We compared our proposed approach against various baseline methods, including Logistic Regression, Random Forest, and XGBoost. We also performed ablation and subgroup analyses, evaluated the quality of learned graph embeddings, and assessed the importance of different edge types in the graph. Results: We included 4,144 stroke patients (mean age 69.2 years; 54.3% men), of whom 3,332 (80.4%) survived their stroke after one year. 30-day, 90-day, and 1-year mortality rates were 9.7%, 13.7%, and 19.6%, respectively. Our proposed approach, StrokeTHG, achieved AUROC of 0.872, 0.878, and 0.837 across horizons, outperforming all tabular baselines. At [&ge;] , 75% specificity, the model identified 5-10 percentage points more mortality cases than the best baseline at each horizon. Subgroup analysis demonstrated consistent performance across sex subgroups and the largest discriminative gains in the Age 65-80 stratum. Edge-type ablation identified phenotype-patient and admission-patient edges in the constructed EHR graph as the most influential relational edges for mortality prediction. StrokeTHG embeddings outperformed all graph and matrix factorization baselines under an identical downstream classifier, confirming that performance gains stem from representation quality rather than classifier capacity. Conclusions: StrokeTHG demonstrates that heterogeneous graph representations of EHR data provide a consistent improvement over flat tabular models for multi-horizon stroke mortality prediction, with particular advantage at clinically actionable sensitivity thresholds and novel multi-horizon monotonic prediction capability. This methodological framework may be adaptable to other EHR-based clinical research studies seeking to leverage heterogeneous relational structures for predictive modeling.

Background: Digital decision-support tools such as triage systems and symptom checkers support millions of health-related decisions each year. Their quality and safety are commonly evaluated using textual patient cases, known as case vignettes. However, existing vignette sets written by medical experts cover only a limited spectrum of real-world patient presentations and lack population weights, which would allow extrapolating evaluation results to the underlying patient population. Objective: This study aims to develop a data-driven framework for automatically generating a human-manageable set of case vignettes from nationwide triage data that captures broad presentation diversity and links each vignette to a quantitative weight reflecting the number of underlying patient assessments. Methods: From 3.2 million triage assessments conducted over one year using structured triage software in the German medical on-call service (telephone triage and online self-triage) and at the joint contact points of the outpatient emergency care service and hospital emergency departments, we randomly sampled 50,000 cases. Triage questionnaires were converted into semantic embeddings using a German Sentence Transformer Model and grouped by agglomerative clustering. For clusters containing sufficient assessments, we generated one representative assessment using a two-phase simulated-annealing optimization. The optimization minimized the distance to the cluster centroid while maximizing the number of answered triage questions, aiming for high representativeness and information content. Each representative assessment was assigned the size of its source cluster as its sample-based weight. A similarity-based sensitivity analysis was performed to examine whether these weights were preserved in the full 1-year population. Finally, the question-answer pairs of the representative assessments were converted into structured textual case vignettes using controlled prompting of a large language model. Results: The cluster analysis yielded 514 included clusters covering 96.8% of the sampled 50,000 assessments. The generated representatives showed strong agreement with the majority treatment-urgency recommendation of their source cluster (Spearman's {rho}=0.78, p<0.001) and contained on average 4.3 more answered triage questions than the original assessments within their clusters. When weighted by cluster size, the representatives approximated the sample distributions of treatment urgency, demographics, and symptoms, although some systematic deviations remained, most notably an overrepresentation of female cases (+13.5%), patients aged 14-49 years (+8.0%), and the urgency category "As soon as possible" (+6.6%). Of 121 recorded symptoms, 101 (83.5%) were covered by the representatives; the rest each occurred in <0.5% of the sample. In a sensitivity analysis, cluster-based vignette weights were strongly correlated with similarity-based population weights (Spearman's {rho}=0.77, p<0.001), and 90.1% of assessments in the full 1-year population were matched to at least one vignette. Conclusions: We present a data-driven framework for deriving a manageable set of population-weighted case vignettes from nationwide triage data. The resulting vignettes captured broad presentation diversity, approximated key sample characteristics, and provided an explicit quantitative link to the number of underlying patient assessments. After medical expert review and refinement, the vignettes may support more population-aware evaluation and quality assurance of digital decision-support tools.

Background Endometrial cancer exhibits marked molecular and immune heterogeneity that is only partially explained by established genomic biomarkers. We investigated whether T cell receptor (TCR) repertoire architecture captures complementary dimensions of antitumor immunity beyond conventional molecular classification. Methods Paired tumor and peripheral blood samples from eight patients with molecularly characterized endometrial cancer underwent TCR repertoire profiling. Diversity, clonality, and tumor blood overlap metrics were integrated with genomic variables, including tumor mutational burden (TMB), genomic instability metric (GIM), and POLE status. Principal component analysis and correlation analyses were used to identify major dimensions of repertoire organization. Composite Immune Focusing and Immune Sharing Scores were derived to summarize dominant repertoire patterns. Results The first two principal components explained 70.1% of total repertoire variance and revealed substantial heterogeneity independent of histological subtype. TMB was strongly associated with reduced repertoire diversity and increased clonal dominance, resulting in a robust association with the Immune Focusing Score ({rho} = 0.88, p = 0.004). POLE mutated tumors occupied the extreme end of this focusing continuum. In contrast, genomic instability was associated with increased tumor blood repertoire overlap and preserved diversity, reflected by a strong correlation between GIM and the Immune Sharing Score ({rho} = 0.76, p = 0.027). The two immune scores showed minimal correlation with each other ({rho} = -0.24, p = 0.57), indicating that they capture largely independent aspects of immune organization. Conclusion Integrative analysis of TCR repertoire architecture and tumor genomics identifies distinct immunogenomic states in endometrial cancer that are not fully captured by conventional molecular classification. If validated in larger cohorts, immune focusing and immune sharing metrics may provide complementary biomarkers for patient stratification and immunotherapy-oriented precision oncology

Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients (P = 3.2x10-5) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.

Skin cancer requires early detection for improved survival rates. Most existing methods rely on deep learning based image classification, which is affected by visual similarity among lesions. Fewer studies use Gene Expression (GE) analysis, which captures molecular characteristics but lacks structural and visual details. To overcome limitations of individual modalities, this paper proposes a multimodal framework integrating dermoscopic images and GE profiles for skin cancer classification. EfficientNet and logistic regression are used for image based analysis and genomic skin lesion profiling, respectively, followed by fuzzy rule based decision systems to reduce uncertainty within individual modalities. Finally, fuzzy fusion combines predictions from both modalities using uncertainty based weighting of classifier outputs. The experimental findings show that both the image based and GE based classification models individually achieved accuracies of nearly 92%. However, the integration of prediction results through the proposed fuzzy fusion strategy further enhanced the classification performance, achieving an overall accuracy of 94.25%. The results obtained outperform contemporary methods, highlighting the effectiveness of combining complementary multimodal information compared with single modality approaches.

The purpose of this work is to analyze the 2-year overall survival (OS2y) of limited-stage small cell lung cancer (LS-SCLC) treated with chemoradiotherapy (CRT), aiming at characterizing the response of LS-SCLC, and in particular the /{beta} value and proliferation parameters. Through a systematic analysis of the literature, we collated a dataset containing 57 entries (3363 patients) of response of LS-SCLC treated with CRT. Radiotherapy schedules ranged from hyper- to hypofractionation. Four radiobiological models to describe the OS2y were investigated, with progressive levels of complexity including the effect of radiotherapy, chemotherapy, treatment year and toxicity. The Akaike Information Criterion (AIC) was used to compare models, and the profile likelihood methodology to compute confidence intervals. Model 4, which includes the effect of radiotherapy, chemotherapy, treatment year and dose-dependent toxicity, provided the best fits of the experimental data (lowest AIC value). While being the best model, model 4 still fails to provide a good prediction of the OS2y, in particular failing to predict the survival of the schedules achieving the lower/higher survivals. The radiobiological analysis of the dose-response of LS-SCLC to CRT does not allow to narrowly constrain the value of response parameters. We attribute this limitation to the large heterogeneity of this disease. Nonetheless, our analysis shows a large /{beta} value (>9 Gy, 95% CI), which implies a low fractionation effect in the radiotherapy of LS-SCLC. and an accelerated proliferation of tumor cells, {lambda}' > 1.6 Gy/day (95% CI), after a kick-off time of ~4-5 weeks, which supports the use of accelerated protocols to avoid the effect of tumor proliferation on the clinical outcome.

Background. Lung metastases in osteosarcoma (OS) are the main cause of the death. The accuracy of the diagnosis of nodules by computed tomography (CT) of the lungs is critically important for determining the disseminated stage of the disease and planning surgical treatment. The use of artificial intelligence (AI) in the search for lung nodules increases the accuracy of diagnosis and reduces the chance of missing metastases. Objective: to evaluate the accuracy of lung nodules diagnosis in adolescents with OS using AI. Methods. A retrospective assessment of CT scans of adolescents with OS was performed. A pathological nodule with an average size of [&ge;]4 mm was considered a target finding. The diagnostic accuracy of an AI algorithm previously trained on an adult dataset was evaluated, and the number of false positives (FP) and false negatives (FN) was determined. Sensitivity, specificity, accuracy, area under the ROC curve (AUC), positive predictive value, negative predictive value, and F1-measure were calculated. Based on the obtained results, the effectiveness of the algorithm was assessed. Results. 248 CT scans of adolescents with OS were evaluated. The following results were obtained: in 5 cases, the AI algorithm showed a FP result (2.02%), in 34 cases, it showed a FN result (13.71%), and in 209 cases, a correct result (both true positive and true negative) (84.27%). The diagnostic accuracy of the algorithm was 0.843 (95% CI 0.794-0.887). The application of the AI algorithm in the practice of an X-ray doctor in a specific clinical task would allow to increase the sensitivity from 0.805 to 0.891, while ensuring an absolute decrease in the number of FN results by 8.59% and a relative decrease by 44%. Conclusion. The obtained results confirm the practical value of the application of the AI algorithm and justify the implementation of AI-assisted systems in the diagnostic protocols for lung metastases in adolescents with OS.

Background: Unstructured data represent about 80% of total electronic health records (EHR) data. Structuring this free text is essential for advancing clinical research, including cohort selection for trials, retrospective studies, and the development of disease registries. While manual chart review (MCR) remains the gold standard for extracting this clinical data, the process is inherently slow, resource-intensive, and susceptible to errors from human fatigue. We evaluated the extraction accuracy, safety, and efficiency of the HeLIX (Hepatology Logic-Integrated Extraction) framework, a Large Language Model (LLM) protocol using Google Gemini 3 Pro, compared to a gold-standard Manual Chart Review (MCR). Methods: A prospective validation study was conducted using 50 high-complexity, simulated hepatology discharge summaries designed to replicate the real-world heterogeneity of EHRs. The HeLIX framework employed a Zero-Shot, Structured Chain-of-Thought (CoT) prompting strategy enforced by a three-layer architecture: Clinical Reasoning Trace, Schema Enforcement, and Evidence Verification. The model extracted 45 distinct clinical variables. Performance was benchmarked against a consensus MCR. Results: Across 2,250 evaluated data points, the model achieved an overall Extraction Accuracy of 99.24% (95% CI: 98.8%-99.5%), with perfect concordance in 35/45 (77.8%) variables. For binary diagnostic variables, the model demonstrated an overall F1-score of 0.98, Recall of 0.99 and substantial inter-rater reliability (Cohens {kappa} = 0.97). Hallucinations were exceptionally rare (2/2250; 0.08%). Critical errors affecting clinical management occurred in only 2 instances (<0.1% of total data), both involving etiological misattribution in complex multifactorial diagnoses. The AI workflow was 13.4-fold faster and 95.1% more cost-effective than manual extraction. Conclusion: The HeLIX framework demonstrates physician-level accuracy and reliability in extracting complex hepatology data. It offers a scalable, efficient, and economical alternative to manual chart review. Such frameworks could accelerate clinical research, enabling healthcare systems globally to build comprehensive patient registries for a fraction of the traditional cost.

Purpose: Pathogenic or likely pathogenic (P/LP) variants are increasingly identified in genes more commonly associated with adult-onset cancer predisposition, but their prevalence and relevance to children who present with cancer remain unclear. Methods: We retrospectively analyzed 1,280 consecutive pediatric patients with cancer who underwent clinical germline sequencing, using a virtual panel, from 2021 to 2024. Genes with P/LP variants were categorized as aoCPG or pediatric-onset cancer predisposition genes (poCPG) according to cancer risk before age 18 years and pediatric surveillance recommendations. Variant relevance was adjudicated using tumor diagnosis/histopathology, immunohistochemistry, and tumor molecular features and classified as primary, secondary, or indeterminate. Results: Among 1,280 patients, 197 (15.4%) harbored 211 P/LP variants across 54 genes. Sixty-six variants (31.3%) occurred in aoCPG, 87 (41.2%) in poCPG, and 58 (27.5%) were heterozygous variants in autosomal recessive genes. Among adult-onset variants, 7 (10.6%) were primary, 54 (81.8%) secondary, and 5 (7.6%) indeterminate. Among pediatric-onset variants, 77 (88.5%) were primary and 10 (11.5%) secondary. Six patients (3 adult-onset variants; 3 pediatric-onset variants) received targeted therapy informed by germline/somatic sequencing results. Conclusion: In pediatric oncology, most variants in aoCPG are secondary rather than tumor-related findings. Tumor-informed interpretation, beyond variant classification, may improve reporting, counseling, and therapeutic decision-making

Background Electronic health record documentation patterns may reflect workflow complexity, monitoring intensity, and operational strain in intensive care settings. However, documentation-derived features can be sensitive to local documentation culture, data capture systems, and outcome definitions. Retrospective validation across multiple datasets is therefore needed before these signals are used in workflow intelligence or clinical AI governance tools. Objective To evaluate whether documentation-density and documentation-timing features show reproducible retrospective signal for ICU workflow complexity and long-stay proxy outcomes across de-identified critical care datasets, while distinguishing workflow and long-stay associations from unsupported claims about mortality prediction, burden reduction, or deployment readiness. Methods We synthesized retrospective validation results from de-identified ICU and workflow datasets generated through a prespecified documentation-density validation program. Feature families included Documentation Burden Score style features, Shift-End Documentation Rate style features, documentation reliability style metadata, and all-documentation feature sets where available. Outcomes included long ICU length of stay proxies, mortality where available, and workflow proxy endpoints. Models compared baseline feature sets with enhanced models containing documentation-density or workflow features. Performance was summarized using area under the receiver operating characteristic curve, Brier score where reported, delta AUROC, bootstrap confidence intervals where reported, and label-shuffle controls where available. Results The strongest external long-stay proxy evidence came from the NWICU chartevents analysis, which included 28,612 ICU stays, 20,267 stays with chart events, and 9,619,759 chart events. For ICU length of stay greater than the median, baseline AUROC was 0.5252. Enhanced AUROC was 0.9512 for Documentation Burden Score features, 0.9214 for Shift-End Documentation Rate features, 0.8470 for documentation reliability style features, and 0.9517 for all documentation features. Corresponding label-shuffle enhanced AUROCs were near random, ranging from 0.4897 to 0.5064. For ICU length of stay greater than the 75th percentile, baseline AUROC was 0.5155. Enhanced AUROC was 0.9433 for Documentation Burden Score features, 0.9194 for Shift-End Documentation Rate features, 0.8118 for documentation reliability style features, and 0.9427 for all documentation features, with label-shuffle enhanced AUROCs from 0.4836 to 0.4999. Additional retrospective support was observed in eICU workflow analyses, HiRID first-24-hour documentation-density analyses, MIMIC-IV HF ICU internal analyses, MIMIC-IV-Note metadata extensions, and nursing-chart or lab density proxy analyses. However, cross-institution discrimination transfer was weak without recalibration, and several analyses remained proxy validations rather than final clinical validations. Conclusions Documentation-density and documentation-timing features show promising retrospective signal for ICU workflow complexity and long-stay proxy outcomes, especially in NWICU chartevents and selected internal dataset-specific analyses. These findings support further preregistered, prospective, silent-mode validation of documentation-derived workflow intelligence. They do not establish prospective clinical performance, mortality reduction, clinician burden reduction, autonomous deterioration prediction, or deployment readiness.

Whole-genome sequencing comprehensively captures coding, non-coding and structural variation in families with suspected inherited disorders, yet its clinical utility remains constrained by an interpretation bottleneck: selecting a handful of relevant variants from millions of candidates. Current rule-based pipelines, anchored in ACMG/AMP criteria, excel at identifying highly penetrant Mendelian alleles but frequently miss variants of low-to-moderate penetrance, non-coding alterations and germline-somatic interactions. Here we introduce PolyCLIP-T, a topology-guided multimodal framework that transforms variant selection from a classification problem into a geometric discovery task. By contrastively aligning DNA-sequence embeddings with functional annotations, PolyCLIP-T constructs a unified latent space in which the displacement between reference and alternate embeddings quantifies the molecular perturbation induced by each variant. Persistent homology then identifies stable topological components - coherent variant groups shared among affected relatives - that transcend single-variant scoring logic. Applied to six families with multi-morbid cancer, autoimmune and cardiovascular disease, PolyCLIP-T recovered non-coding and structural candidates overlooked by conventional pipelines and revealed pleiotropic networks spanning disease categories. This approach provides an interpretable, scalable solution for genome-first investigations of disorders driven by polygenic architectures that evade single-variant analysis. The framework was developed and benchmarked on deeply characterised familial cohorts selected for transgenerational multimorbidity; validation in larger, independent populations will be essential to establish its generalisability. An interactive web tool is freely available at https://www.polyclip-t.uma.es/.